Nattokinase improves blood flow by inhibiting platelet aggregation and thrombus formation.

Abstract

The effects of nattokinase on the in vitro platelet aggregation and in vivo thrombosis were investigated in comparison with aspirin. Rabbit platelet-rich plasma was incubated with nattokinase and aggregation inducers collagen and thrombin, and the platelet aggregation rate was analyzed. Nattokinase significantly inhibited both the collagen- and thrombin-induced platelet aggregations. Nattokinase also reduced thromboxane B2 formation from collagen-activated platelets in a concentration-dependent manner. Rats were orally administered with nattokinase for 1 week, and their carotid arteries were exposed. Arterial thrombosis was induced by applying 35% FeCl3-soaked filter paper for 10 min, and the blood flow was monitored with a laser Doppler probe. Nattokinase delayed the FeCl3-induced arterial occlusion in a dose-dependent manner, doubling the occlusion time at 160 mg/kg. In addition, a high dose (500 mg/kg) of nattokinase fully prevented the occlusion, as achieved with aspirin (30 mg/kg). The results indicate that nattokinase extracted from fermented soybean inhibit platelet aggregation by blocking thromboxane formation, and thereby delay thrombosis following oxidative arterial wall injury. Therefore, it is suggested that nattokinase could be a good candidate without adverse effects for the improvement of blood flow.

• Authors: Ja-Young Jang, Tae-Su Kim, Jingmei Cai, Jihyun Kim, Youngeun Kim, Kyungha Shin, Kwang Sei Kim, Sung Kyeong Park, Sung-Pyo Lee, Ehn-Kyoung Choi, Man Hee Rhee, Yun-Bae Kim
• Journal: Laboratory animal research (Lab Anim Res) Vol. 29 Issue 4 Pg. 221-5 (Dec 2013) ISSN: 1738-6055 [Print] England
• PMID: 24396387 (Publication Type: Journal Article)